DiaPat Heart failure and coronary heart disease Test + CKD-273+7 Test
Description DiaPat Heart failure and coronary heart disease Test + CKD-273+7 Test , biomolecular detection of cardiovascular and kidney diseases
In view of the new legal situation for in-vitro diagnostics of the new EU directive, all DiaPat tests, such as urine samples, are only to be carried out under the instruction of a doctor and only through him the diagnostic results are giving to the patient. *
* You can still order the self-payer test from us, receive the test set after payment and take it to your doctor. The instructions for your doctor are attached.
Please also read our Product data sheet and the recommendations/instructions at the end of this page.
The DiaPat® KardiOM + RenOM Test consists of the following two individual tests
DiaPat Heart failure and coronary heart disease Test
The DiaPat Heart failure and coronary heart disease Test is a test in urine that predicts the risk of heart failure caused by calcified arteries (arteriosclerosis). Before the first clinical symptoms occur, the DiaPat Heart failure and coronary heart disease Test test very reliably detects even the smallest, not yet visible plaque deposits by analyzing 238 arteriosclerosis-specific proteins. The test is currently the only diagnostic tool available to detect plaques at this early stage. Based on these test characteristics, the DiaPat Heart failure and coronary heart disease Test test ensures timely diagnosis and significantly improves the success of therapy so that heart attack and ischemic stroke can be prevented. The DiaPat Heart failure and coronary heart disease Test is a clinically validated valuable method for early detection and subsequent therapy guidance.
By the analysis of kidney disease-specific proteins in the urine, the DiaPat-CKD-273+7 Test enables early detection and differentiation of chronic kidney diseases. The urine test has been validated in a variety of clinical studies. It reliably detects pathologic changes in the kidneys before persistent organ damage occur. Timely therapy after a positive DiaPat-CKD-273+7 Test result can delay or prevent the complete loss of kidney function and the necessity for kidney replacement therapy (dialysis or kidney transplantation) that is then required. The DiaPat-CKD-273+7 Test differentiates between the following chronic kidney diseases:
- Diabetic nephropathy
- Minimal Change Disease (MCD)
- Membranous glomerulonephritis (MGN)
- Focal segmental glomerulosclerosis (FSGS)
- IgA-nephropathy (IgAN)
- Lupus nephritis
- Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
Instructions for use
For the DiaPat® test, the midstream of second morning urine is collected in a urine cup. The urine is then transferred to the enclosed urine monovette (sample syringe) *. The urine monovette is placed in protective packaging* for transport. Transport to the laboratory will be carried out per overnight express (see also instructions for use).
*These materials will be provided as part of the DiaPat® sample collection kit
The DiaPat® Kombi-test includes the following services:
The DiaPat® package includes the sample set for collecting the urine sample and all the necessary documents. The shipment will be operated by a courier by home pickup or via the doctor's office.
The analysis will be conducted in our central laboratory using the CE-MS technology.
Medical history questionnaire form
A detailed medical history questionnaire is part of the sampling kit. Please fill it out carefully and completely. The information is the basis for a reliable evaluation of the DiaPat® test result.
Send the result letter to your family doctor
The result of the protein analysis, which we send to your doctor, is explained in detail and gives recommendations for further diagnostic steps.